Close menu
Open menu
Potential novel immuno-oncology mechanism revealed during translational Phase I immuno-blood profiling of experimental ADC medicine OBT076 in a gastric cancer patient.
Phase 1 study of OBT076, first in class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy and PK/PD results
Phase 1 study of OBT076, first in class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy and PK/PD results
Identification and validation of a novel immuno-oncology target and selection of a therapeutic antibody candidate with a pharmacologically beneficial activity profile
Targeting CD205 with the antibody drugconjugate MEN1309/OBT076 is an active newtherapeutic strategy in lymphoma models
MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
AACR Annual Meeting 2018, Chicago, Illinois
Harnessing novel immune escape mechanisms for cancer therapeutics: OXAB1 target validation, proof of concept and preclinical development